Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus KEFLEX.
CEFOBID vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic